Lupin launches tablets in US to treat infections
New Delhi: Drug firm Lupin said it has launched in the American market Doxycycline Hyclate tablets USP, used for treating various infections.
The 75 mg and 150 mg tablets were launched after receiving the approval for the from the United States Food and Drug Administration (USFDA), Lupin said in a filing to BSE.
They are generic versions of Aqua Pharmaceuticals, LLC's Acticlate tablets in the same strengths, it added.
"They are indicated in the treatment of infections caused by various micro-organisms and as an adjunctive therapy in severe acne," Lupin said.
As per the IMS MAT June 2017 data the tablets had annual sales of approximately USD 263 million in the US, it added.
Shares of Lupin Ltd rose 3.26 percent to Rs 1,060.90 on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd